Home › Employers › CuriRx Inc.
CuriRx Inc.: H-1B salaries and sponsorship
CuriRx Inc. filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $80,000.
Does CuriRx Inc. sponsor H-1B visas?
CuriRx Inc. filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on May 16, 2024. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Formulation Scientist | 1 | $80,000 |
| Senior Bioprocess Engineer | 1 | $120,000 |
| Marketing Research Analyst | 1 | $68,000 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2023 | 2 | $100,000 |
| FY2024 | 1 | $68,000 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
- Biochemists and Biophysicists1
- Bioengineers and Biomedical Engineers1
- Market Research Analysts and Marketing Specialists1
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Marketing Research Analyst | $68,000 Level II | Wilmington, MA | May 16, 2024 | Jun 3, 2024 | Certified, then withdrawn |
| Senior Bioprocess Engineer | $120,000 E-3 · Level II | Wilmington, MA | Jul 13, 2023 | Jul 31, 2023 | Certified |
| Formulation Scientist | $80,000 Level I | Wilmington, MA | May 16, 2022 | Oct 1, 2022 | Certified, then withdrawn |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).